" class="no-js "lang="en-US"> 3D Bioprinting Market Size to Reach USD 2,687.8 Million in 2027 - Medtech Alert
Friday, May 24, 2024

3D Bioprinting Market Size to Reach USD 2,687.8 Million in 2027

The global 3D bioprinting market size is expected to reach USD 2,687.8 Million in 2027 at a CAGR of 20.7% during the forecast period, according to the recent report by Emergen Research. Rapid technological advancements in 3D bioprinters, increasing investment to accelerate research and development activities of bioprinters, and rising use of 3D bioprinters to develop biomaterials for drug research and regeneration of joints and ligaments are key factors expected to drive market revenue growth over the forecast period. In addition, numerous advantages of 3D bioprinting in organ reconstruction to treat various end-stage disorders is another key factor contributing to the revenue growth of the market.

3D bioprinting leverages techniques similar to additive manufacturing to mix up growth factors, cells, and biomaterials to create biomedical parts that can mimic natural tissue attributes. 3D bioprinting leverages layer-by-layer technique to add materials called as bioinks to create tissue-like structures that can be used in medical and tissue engineering procedures. Recent advancements in the technique has expanded its scope in drug design and development by creating target tissues and cells for drug research and testing. In addition, 3D bioprinters can be used to reconstruct tissues from any body part and this has further increased its applications for treating various severe and chronic disorders. Significant progress in tissue engineering and production of biomaterials have contributed considerably to the 3D bioprinting market growth.

3D bioprinters have been extensively used in vaccine research during the COVID-19 pandemic. Bioprinting is widely being used in the development of regenerative medicines, stem cell therapies, drug research and therapies, and tissue and organ reconstruction. Increasing application of 3D bioprinting in cosmetic and pharmaceutical sector is also a key factor contributing to the revenue growth of the market going ahead. However, lack of skilled professionals and technical knowledge, high costs of 3D bioprinting, and limited access to advanced technologies in developing and underdeveloped countries are some key factors expected to restrain market growth to a significant extent over the forecast period.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more